Business Update

RNS Number : 2335P

Syntopix Group plc

30 September 2011

 



Press Release

30 September 2011

Syntopix Group plc

("Syntopix", "the Company" or "the Group")

Business Update

Syntopix Group plc (AIM:SYN), the dermatological experts delivering healthcare innovation to the cosmetic, consumer healthcare and pharmaceutical industries, is pleased to provide a business update for the period ended 31 July 2011 ahead of the Group's final results which will be announced on Tuesday, 29 November 2011.

As announced on 27 September 2011, the Group will be holding a General Meeting on 20 October 2011 at which shareholders will vote on a special resolution proposing that the name of the Group is changed to Evocutis plc.

Following the acquisition of Leeds Skin in May 2011, the Board is pleased to announce that the integration of that business with Syntopix is in line with the Board's expectations. The Company is progressing with the development of a new brand to reflect the strengths of the combined business; and the businesses are now located at one specialised facility in Wetherby, Yorkshire.

The combined Group now has three business divisions:

1.   Clinical Research Services in dermatology

2.   LabSkin^TM - a proprietary human skin model to certify the efficacy of dermatology products

3.   Consumer skin care products

Dr Steve Jones, CEO of Syntopix, commented: "We are pleased to report that the reorganisation of the business is complete, following the acquisition of Leeds Skin in May 2011, and we are now leveraging the considerable synergy of the customer bases from the two companies. We believe that the three facets of the business will enable the Company to generate revenues in the immediate, mid, and long-term. 

"Our Clinical Research Services division is revenue generating, and has an impressive blue-chip client base.

"The LabSkin^TM division has already developed and validated its first model to assess the efficacy of anti-dandruff products. Further skin model systems are in validation and development, and will be announced in due course. The LabSkin^TM model will enable our customers to generate qualitative data on their compounds and products which, we believe, surpasses other laboratory-based research, and will allow for more scientific and evidence-based labelling.

"In the longer term, the business is developing a range of skin care products. The first range will be moisturisers for all aspects of dry skin.

"In conclusion, this is an extremely exciting time for the business. The bringing together of Syntopix and Leeds Skin has created a business that is sustainable with near term revenues, and we believe will have significant long-term upsides. We look forward to updating shareholders on further progress in due course."

- Ends -

For further information, please contact:

Syntopix Group plc
Dr Stephen Jones, Chief Executive Officer	[phone]
Tom Bannatyne, Chairman	www.syntopix.com

Zeus Capital Ltd
Tom Rowley	Tel: [phone]
Andrew Jones	www.zeuscapital.co.uk

XCAP Securities Plc
Karen Kelly/Jon Belliss/Adrian Kirk	Tel: [phone]
	www.xcapgroup.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins/Adam Michael/Jamie Hooper	Tel: [phone]
[e-mail]	www.abchurch-group.com

Notes to editors

About Syntopix Group plc

With a rich portfolio of new product opportunities Syntopix offers antimicrobial expertise to the cosmetic, consumer healthcare and pharmaceutical industries.

Additionally, Syntopix is uniquely able to combine research for laboratory testing, advanced skin models and clinical testing to offer a complete service for the development of skin care products and ingredients. Through research and testing we enable you to advance the discovery of skin care products that actually work.

Syntopix works with companies at all stages of the product development pipeline offering R&D solutions from ownable technology platforms through to tailored research, and now provides an independent commercial testing facility to the pharmaceutical and healthcare industries. Unique characteristics of its colonised full thickness model of human skin (LabSkin^TM) allow rapid, cost effective screening of e.g. anti-aging, anti-inflammatory and antimicrobial ingredients and products for use on skin.

Syntopix also offers high quality contract research services specialising in Human Skin Microbiology, tissue culture systems and Human Volunteer and Clinical Dermatology Research.

When it comes to topical antimicrobial innovation the Syntopix focus is simple: intelligent and specialised R&D input. 

For further information, please see www.syntopix.com.

 

END

 

 

MSCSEIFIUFFSEDU